Houston-based C4 Imaging, LLC, announces that Isoray Medical, Inc. has received U.S. FDA 510(k) clearance for the use of C4 Imaging’s Sirius positive-signal MRI markers with Isoray’s Cesium-131, brachytherapy seeds.
Sirius is implanted during the treatment of prostate cancer with brachytherapy and is used to facilitate brachytherapy seed localization within the prostate utilizing a single post-implant MRI procedure. This allows the benefits of MRI-assisted brachytherapy, also known as MRI-assisted radiosurgery or MARS, to be made available to all prostate cancer patients treated with brachytherapy.
“This is a significant milestone,” says Andrew Bright, president and CEO of C4 Imaging. “Sirius MRI Markers will enable Isoray’s customers to fully utilize the benefits of MRI seed localization. We’re delighted to partner with Isoray. They are leading innovators in the use of brachytherapy to treat prostate cancer, as well as other tumors, and recognize the potential of MRI to optimize treatment quality and patient care.”
Isoray CEO Lori Woods adds: “This achievement represents another step forward in Isoray’s leadership in providing effective prostate cancer therapeutic tools to patients and the doctors who treat them. We are excited to partner with C4 Imaging and bring together the benefits of their innovative technology and our proprietary isotope to achieve new strides in the ongoing fight against prostate cancer.”
